(Q36607385)

15 August 2017

1 reference

title

Drotrecogin alfa (activated) in the treatment of severe sepsis (English)

1 reference

15 August 2017

0 references

1 reference

1

Jean-Louis Vincent

1 reference

15 August 2017

publication date

1 August 2006

1 reference

Expert Review of Anti-infective Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

4

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

537-547

1 reference

Sepsis in European intensive care units: results of the SOAP study.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

The epidemiology of sepsis in the United States from 1979 through 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

21 January 2018

Why sepsis trials fail

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Why immunomodulatory therapies have not worked in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

The interaction between anticoagulant protein S and complement regulatory C4b-binding protein (C4BP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Protein C replacement in severe meningococcemia: rationale and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Low levels of protein C are associated with poor outcome in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Severe protein C deficiency predicts early death in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Activated protein C versus protein C in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Effects of drotrecogin alfa (activated) in human endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Assessing the use of activated protein C in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Activated protein C: do more survive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Evidence-based medicine in the ICU: important advances and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Microvascular blood flow is altered in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Activated protein C variants with normal cytoprotective but reduced anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Neutralization of endotoxin by a phospholipid emulsion in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Molecular diagnostics of injury and repair responses in critical illness: what is the future of "monitoring" in the intensive care unit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

Drotrecogin Alfa (Activated) in Severe Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.4.537

21 January 2018

Identifiers

DOI

10.1586/14787210.4.4.537

1 reference

15 August 2017

1 reference